The US Internal Revenue Code has numerous regulations which must be adhered to in order for companies to reach compliance standards. One such regulation, Section 409A of the IRC, governs the complexities of setting strike prices for employee stock options and requires that companies be properly audited before issuing stock options as employee compensation. Often … Continue reading Whitepaper: Life Sciences – 409A valuation vs. valuation to raise money
Zurich, 25th March 2019 Biotechgate announces the launch of a clinical trial database with more than 460,000 trial records. Clinical trial data is imported from more than 13 registries around the world and continuously updated and catalogued. Thanks to the use of newly developed smart software components, the data is presented in a well-structured and … Continue reading Biotechgate announces the launch of a clinical trial database
Switzerland, March 2019: Venture Valuation has been working with Ferring Pharmaceutical supporting the company with external, third-party product/asset valuations of potential in-licensing opportunities. After Ferring had identified a specific opportunity and deemed interesting to move it forward in the internal evaluation process, Venture Valuation was mandated to review the product/opportunity from an external point of … Continue reading Whitepaper: Collaboration of Venture Valuation and Ferring Pharmaceuticals
Inspired by co-founder Lea von Bidder’s concept, the Ava bracelet is becoming an indispensable device for women to monitor their own biological rhythms. Venture Valuation (VV) interviewed Vicky Kummer, Global Brand Manager. Read the interview Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
Zurich/Berlin, January 2019; Venture Valuation entered into a partnership with HEALTH MADE IN GERMANY, the export promotion program for the German healthcare industry initiated by the German Federal Ministry for Economic Affairs and Energy. HEALTH MADE IN GERMANY is implemented by Germany Trade & Invest (GTAI), the country’s economic development agency. It is Venture Valuation’s … Continue reading Biotechgate, HEALTH MADE IN GERMANY and Germany Trade & Invest (GTAI) to map German Life Science Industry
14 January 2019. Last week saw the annual J.P. Morgan Healthcare Conference held in San Francisco. Venture Valuation and Biotechgate was represented by CEO, Patrik Frei and Senior Business Development Executive Ray Carroll providing their insights into the industry announcements. It was again a busy week in San Francisco kicking off the Bio year 2019 … Continue reading J.P. Morgan Healthcare Conference Round-up by Venture Valuation / Biotechgate
Invented by Prof. Hiroshi Kobayashi, Department of Mechanical Engineering, Tokyo University of Science, the Muscle Suit® is becoming an indispensable device for the elderly care services as well as many other heavy lifting tasks. Venture Valuation (VV) interviewed Takashi Furukawa, CEO. Read the interview Would you like to be notified about new reports and other … Continue reading Interviews with leading Life Sciences companies: Innophys Co.
Zurich / Montréal, November 26, 2018 As part of the ongoing commitment of Montréal InVivo to promote the economic development and growth of the life sciences and health technologies (LSHT) sector in Québec, Biotechgate, a company owned by Venture Valuation, and Montréal InVivo, the LSHT industrial cluster of the Montreal metropolitan area, announce a partnership … Continue reading Launch of a Directory of Life Sciences and Health Technologies companies with an exclusive database in Québec
RESI Conference, Boston, Sep 2018, 36 pages Deal and Product Valuations Deal and Product Valuations
Continuing a trend that began in 2017, this year has seen the rise of big investment deals in the biotech sector. Smaller biotechs are also cashing in as Big Pharma look to fill dwindling pipelines; according to Bloomberg data, biotech acquisitions are expected to be at the highest level for 12 years. Analysing this data from … Continue reading Whitepaper: The Rise of Bigger, Earlier M&A Deals for Biotech
